Nab-PTX Plus S-1 and Sintilimab as Adjuvant Therapy in Patients With Stage IIIC Gastric Cancer

  • STATUS
    Recruiting
  • End date
    Mar 1, 2024
  • participants needed
    38
  • sponsor
    Ruijin Hospital
Send
Updated on 14 March 2021
See if I qualify

Summary

In this study, we combine Nab-PTX, S-1 and sintilimab as adjuvant regimen to patients with stage IIIC GC. We are aiming to investigate the recommended dose of this regimen in a phase I study and estimate the toxicity and efficacy of this regimen in a phase II study.

Description

The phase I study is a dose-escalation study using a standard 3+3 design. The regimen involves 3-week cycles with escalated doses of nab-paclitaxel (80-120 mg/m2 on days 1 and 8) and fixed doses of sintilimab (200 mg on day 1) and S-1 (based on body-surface area on day 1 to 14). The primary endpoints are safety and determination the recommended dose in the subsequent phase II study. In the phase II trial, the primary endpoint is 3-year relapse-free survival (RFS). Secondary endpoints are 5-year overall survival (OS), 3-year OS, 5-year RFS, and quality of life. Exploratory endpoint is time to peritoneal metastasis. Adverse events are monitored and graded according to the Common Terminology Criteria for Adverse Events version 4.0.

Details
Condition Stage IIIC Gastric Cancer
Treatment Nab-PTX, Sintilimab, S-1
Clinical Study IdentifierNCT04781413
SponsorRuijin Hospital
Last Modified on14 March 2021

Eligibility

 Yes No Not Sure

Inclusion Criteria

18 years to 80 years
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
Primary gastric cancer or gastroesophageal junction cancer that is pathologically diagnosed as adenocarcinoma
Patients who have underwent radical resection with D2 lymphadenectomy and histologically proven to be stage IIIC gastric cancer according to the 8th edition of the UICC/AJCC TNM staging system for gastric cancer[29]
Patients who have received no prior chemotherapy or radiotherapy or immunotherapy for gastric cancer or gastroesophageal junction cancer
No peritoneal metastasis by laparoscopy and no tumor cells in peritoneal fluid on cytologic analysis
Adequate organ function for chemotherapy as follows
absolute neutrophil count of 1.5109/L
platelet count of 100109/L
hemoglobin 90g/L
bilirubin of <1.5upper limit of normal [ULN]
alanine aminotransferase and aspartate aminotransferase of <2.5ULN
serum creatinine of 1.5ULN
creatinine clearance of >50 mL/min
TSH 1ULN (if abnormal, T3 and T4 levels should be inspected at the same time, if T3 and T4 levels are normal, they can be included in the group)
APTT 1.5ULN and INR 1.5ULN
myocardial enzymogram 1ULN
Written (signed) informed consent
Good compliance with the study procedures, including examination and treatment
Surgeons should have experience doing this type of surgery (>50 procedures per year)
Patients have recovered from the operation and have no unresolved postoperative complications (such as postoperative infection, anastomotic leakage, gastrointestinal bleeding, pancreatic leakage) during baseline evaluation
Start first treatment between 4 weeks and 12 weeks after surgery and there is no potential disease recurrence at the baseline evaluation
The serum or urine HCG test of the female patients of non-surgical sterilization must be negative within 72 hours before the study group for the female patients of non-surgical sterilization or childbearing age
During the study treatment period and within 3 months after the end of the study treatment period, a medically recognized contraceptive measure (such as IUD, contraceptive pill or condom) should be used for the enrolled patients

Exclusion Criteria

Distant metastatic disease evaluated by Chest-abdomen-pelvis CT, bone scan and head MR when with central nervous system symptoms or PET-CT
R1 or R2 surgical margins
Hospital stays exceeding 60 days
Patients with history of prior or concurrent malignant tumors. However, subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma, are eligible
Patients who received study drug treatment within 4 weeks before enrollment (participate in other clinical trials)
Patients with serious complications such as
Uncontrolled cardiovascular disease, angina and arrhythmia
Myocardial infarction in past six months
Uncontrolled diabetes mellitus
History of receiving anti-PD-1, anti-PD-L1, anti-PD-L2 or any other T cell co-simulation or checkpoint inhibitor therapy (eg. CTLA-4, OX-40, CD137)
Received any anti-cancer for this disease, including chemotherapy or radiotherapy or immunotherapy or Chinese traditional herb therapy
Refuse to provide blood/tissue sample
Female patients who are pregnant or lactating, or planning to become pregnant or lactating
Active autoimmune disease or history of refractory autoimmune disease; Subjects with hypothyroidism requiring only hormone replacement therapy and skin diseases without systemic treatment (such as vitiligo, psoriasis or alopecia) can be selected
Steroid or other systemic immunosuppressive therapy was used 14 days before admission, excluding local or physiological doses of systemic glucocorticoids (eg. no more than 10mg/day of prednisone or other glucocorticoids of equivalent dose) by nasal spray, inhalation or other routes, or hormones used to prevent allergy of contrast agents
Uncontrollable pleural effusion, pericardial effusion or ascites
History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation
Patients with history of hypersensitivity to any drugs in this study
It may affect the absorption of S-1 in patients with upper gastrointestinal obstruction /bleeding, abnormal digestive function or malabsorption syndrome
Have not fully recovered from toxicity or complications caused by any intervention before starting treatment
HIV antibody positive, active hepatitis B or C (hepatitis B: HBsAg positive and HBV DNA 10 copies/ml; hepatitis C: HCV antibody and HCV-RNA positive, requiring antiviral treatment at the same time)
Receive live attenuated vaccine within 4 weeks before the first dose of study treatment or during the study period
Severe or uncontrolled systemic disease
severe cardiovascular diseases such as symptomatic coronary heart disease, congestive heart failure level II, uncontrolled arrhythmia and myocardial infarction within 12 months before admission
active infection which requires systemic treatment
active tuberculosis
central nervous system (CNS) disorder or peripheral nervous system disorder or psychiatric disease
history of primary immunodeficiency
complicated with severe uncontrolled concurrent infection or other serious uncontrolled concomitant diseases, moderate or severe renal injury
Other factors that may affect the safety or test compliance of the subjects according to the judgment of the researchers
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note